

CORRIGENDUM


## Total Lymphocyte Count, Neutrophil-Lymphocyte Ratio, and Platelet-Lymphocyte Ratio as Prognostic Factors in Advanced Non-Small Cell Lung Cancer with Chemoradiotherapy [Corrigenudm]

Song X, Chen D, Yuan M, Wang H, Wang Z. *Cancer Manag.* 2018;10:6677–6683

On page 6677, Abstract, Results subheading, the median baseline PLR should be 136.1.

On page 6680, Results section, 2<sup>nd</sup> paragraph, the median baseline PLR should be 136.1.

On page 6680, the red curve should be PLR  $\geq$ 136.1 and the blue cure should be PLR <136.1. The COX analysis was not correct in the previous publication and it has been revised and shown below in the new Tables 1 and table 2. The correct Figure 3 is shown below.



**Figure 3** Kaplan–Meier plots of overall survival among patients who receivedchemoradiotherapy for advanced NSCLC stratified by baseline PLR. **Abbreviations:** NSCLC, non–small cell lung cancer; PLR, platelet-to-lymphocyteratio.

On page 6680, Table 2, the COX analysis was not correct in the previous publication and it has been revised. The correct Table 2 is shown below.

Table 2 Univariate analysis of factors potentially associated with overall survival

Characteristics	HR	95% CI	P Value	
Age ≥65	0.778	0.609-0.994	0.045	
Male	0.935	0.733-1.193	0.588	
KPS score ≥70	1.100	0.762-1.588	0.611	
TNM stage IIIB	1.024	0.763-1.375	0.874	
Current smoker	0.918	0.748-1.126	0.412	
Receipt of induction	1.127	0.881-1.443	0.342	
chemotherapy				
Receipt of concurrent	0.868	0.660-1.143	0.314	
chemotherapy				
Pretreatment TLC ≥2.4 × 10 <sup>3</sup> /μL	0.594	0.464-0.759	<0.001	
Pretreatment NLR ≥3.4	2.280	1.776–2.927	<0.001	
Pretreatment PLR ≥136.1	1.745	1.364-2.232	<0.001	

**Abbreviations:** HR, hazard ratio; Cl, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; TNM, tumor-nodes-metastasis; TLC, total lymphocyte count; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.

On page 6681, Table 3, the COX analysis was not correct in the previous publication and it has been revised. The correct Table 3 is shown below.

**Dove**press Song et al

Table 3 Multivariate analysis of factors potentially associated with overall survival Model I (TLC included)

	Model I (TLC Included)			Model 2 (NLR Included)			Model 3 (PLR Included)		
	HR	95% CI	P Value	HR	95% CI	P Value	HR	95% CI	P Value
Characteristics									
Age ≥65	0.902	0.697-1.167	0.431	0.858	0.67-1.099	0.226	0.825	0.645-1.054	0.124
Pretreatment TLC ≥2.4 × 10 <sup>3</sup> /μL	0.613	0.474-0.794	<0.001						
Pretreatment NLR ≥3.4				2.231	1.734-2.87	<0.001			
Pretreatment PLR ≥136.1							1.71	1.333-2.185	<0.001

Abbreviations: HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; TNM, tumor-nodes-metastasis; TLC, total lymphocyte count; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.

The authors have advised errors were caused by carelessness and mis-operation in statistics.

The authors apologize for this error and advise it does not affect the results of the paper.

## Cancer Management and Research

## Publish your work in this journal

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient.

The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/cancer-management-and-research-journal

**Dovepress**